Across TCGA pan-cancer cohorts, RAP2A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RAP2A data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RAP2A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAP2A expression acts as an unfavorable survival marker.
LUAD and KIRP are the cancer types where RAP2A Mutation most reproducibly stratifies survival.